Denali Experiences Slight Delay as FDA Pauses Initiation of Rare Disease Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy DNLI?
Source: Benzinga
FDA Clinical Hold on Denali's DNL952: The FDA has placed a clinical hold on Denali Therapeutics' IND application for DNL952, requesting protocol amendments related to safety monitoring and dosing due to preclinical hypersensitivity reactions observed in mouse models.
Pipeline Updates: Denali provided updates on its development pipeline, including the ongoing review of tividenofusp alfa for MPS II, with a target action date of April 5, 2026, and plans for a Phase 1/2 study of DNL126 for MPS IIIA expected to support accelerated approval by 2027.
Royalty Pharma Funding Agreement: Royalty Pharma announced a $275 million synthetic royalty funding deal based on future sales of tividenofusp alfa, contingent on Denali achieving FDA accelerated approval, with an initial payment of $200 million upon closing.
Analyst Ratings and Stock Performance: Analysts have reiterated positive ratings for Denali Therapeutics, with BTIG maintaining a Buy rating and Wedbush raising its price forecast, while the company's stock was down slightly to $20.09 at the time of publication.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNLI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNLI
Wall Street analysts forecast DNLI stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.000
Low
25.00
Averages
32.78
High
40.00
Current: 21.000
Low
25.00
Averages
32.78
High
40.00
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Denali Therapeutics Reports Q4 Results and Stock Offering
- Earnings Report: Denali Therapeutics reported a Q4 GAAP EPS of -$0.73, aligning with market expectations, indicating stability in financial transparency despite ongoing losses.
- Cash Reserves: As of December 31, 2025, Denali's cash, cash equivalents, and marketable securities totaled approximately $966.2 million, providing a solid liquidity foundation for future R&D and operational needs.
- Stock Offering Announcement: Denali Therapeutics announced a proposed stock offering priced at $17.50 per share, aiming to raise $200 million, which will support its ongoing clinical trials and business expansion efforts.
- Market Reaction: The news of the stock offering may exert short-term pressure on the stock price; however, the influx of capital is expected to facilitate advancements in the company's research on neurodegenerative diseases in the long run.
See More
Shifting Trends in Biotechnology Mergers and Acquisitions
- Evolving M&A Strategies: Pharmaceutical companies are increasingly prioritizing clinical-stage and late-stage programs, particularly those supported by clear human data, indicating a market preference for mature assets that demonstrate safety and efficacy.
- OT-101 IP Expansion: Oncotelic Therapeutics recently announced the expansion of international intellectual property coverage for OT-101, enhancing protection across neurology, oncology, and CNS drug delivery technologies, thereby solidifying its market position in these areas.
- Importance of Clinical Validation: Biopharmaceutical deal activity reflects a growing preference for programs that have achieved clinical validation, particularly in oncology and CNS, highlighting investors' focus on reducing development risks associated with drug discovery.
- Cross-Applicability Platforms: Oncotelic's TGF-β modulation strategy illustrates its broad application potential across oncology and neurological diseases, indicating the company's pursuit of greater market opportunities across multiple indications, thereby enhancing its long-term strategic value.
See More
REGENXBIO Faces FDA Challenges for Gene Therapy Approval
- FDA Response Letter Issued: REGENXBIO's shares fell after receiving a response letter from the FDA regarding its Hunter syndrome gene therapy, indicating regulatory concerns about trial design that could delay the approval timeline.
- Trial Design Concerns: The FDA's questioning of the trial design may impact the efficacy assessment of the therapy, negatively affecting REGENXBIO's market outlook and increasing uncertainty for investors.
- Approval Timeline Delayed: Due to the FDA's feedback, REGENXBIO may need to reevaluate its clinical trial plans, which will push back the originally scheduled approval timeline and affect the company's future revenue expectations.
- Negative Market Reaction: The stock price decline following the FDA's response letter reflects market concerns about REGENXBIO's future direction, potentially leading to decreased investor confidence and impacting its ability to raise funds.
See More
REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
- FDA Approval Update: The FDA has accepted REGENXBIO's RGX-121 BLA under the accelerated approval pathway; however, the PDUFA goal date has been extended from November 9, 2025, to February 8, 2026, indicating the agency's cautious approach to expedited approvals.
- Reasons for CRL: The FDA issued a Complete Response Letter (CRL) for RGX-121, citing concerns regarding study eligibility criteria and the appropriateness of a surrogate endpoint, suggesting that new studies and long-term follow-ups may be necessary, which poses challenges in an ultra-rare disease population.
- Market Reaction: Despite regulatory hurdles, REGENXBIO's stock shows strong momentum in the market, with analysts maintaining a
See More
Denali Therapeutics Advances in Hunter Syndrome Treatment
- Clinical Trial Update: Denali Therapeutics reported significant biomarker reductions in its Phase 1/2 trial for Hunter syndrome (MPS II), with tividenofusp alfa (DNL310) achieving an 80% mean reduction in cerebrospinal fluid heparan sulfate, indicating its potential to address the full disease spectrum.
- Launch Readiness: The company is preparing for the April 5, 2026 PDUFA date, with plans to submit a Biologics License Application (BLA), which would provide much-needed treatment options for patients with Hunter syndrome.
- Sanfilippo Syndrome Research: Preliminary data from the Phase 1/2 study of DNL126 (ETV:SGSH) in Sanfilippo syndrome showed an 83% mean reduction in cerebrospinal fluid heparan sulfate among 20 participants, offering new hope for treatment in a field lacking effective therapies.
- Pompe Disease Clinical Design: Denali presented the Phase 1 clinical study design for DNL952 (ETV:GAA) in Pompe disease, aimed at evaluating safety and tolerability across different dosing regimens, highlighting the therapeutic potential for muscle and nervous system manifestations.
See More
Denali Therapeutics Presents Clinical Data at WORLDSymposium 2026
- Clinical Data Presentation: Denali Therapeutics will showcase clinical and preclinical data from its Enzyme Transport Vehicle (ETV) programs at the 2026 WORLDSymposium, highlighting the potential for delivering enzyme replacement therapies throughout the body, including the brain.
- FDA Priority Review: The Biologics License Application for DNL310 (for Hunter syndrome) is under FDA Priority Review, with a decision expected by April 5, 2026, which could expedite its market entry.
- Multiple Oral Presentations: Two oral presentations will discuss clinical study data for DNL310 and DNL126 (for Sanfilippo syndrome type A), demonstrating the company's progress in rare disease research.
- Poster Presentation Content: Denali will also present several posters, including a health outcomes analysis for MPS II patients and the study design for DNL952 (for Pompe disease), further solidifying its leadership in rare disease treatments.
See More
Denali Therapeutics Reports Q4 Results and Stock Offering
- Earnings Report: Denali Therapeutics reported a Q4 GAAP EPS of -$0.73, aligning with market expectations, indicating stability in financial transparency despite ongoing losses.
- Cash Reserves: As of December 31, 2025, Denali's cash, cash equivalents, and marketable securities totaled approximately $966.2 million, providing a solid liquidity foundation for future R&D and operational needs.
- Stock Offering Announcement: Denali Therapeutics announced a proposed stock offering priced at $17.50 per share, aiming to raise $200 million, which will support its ongoing clinical trials and business expansion efforts.
- Market Reaction: The news of the stock offering may exert short-term pressure on the stock price; however, the influx of capital is expected to facilitate advancements in the company's research on neurodegenerative diseases in the long run.
See More
Shifting Trends in Biotechnology Mergers and Acquisitions
- Evolving M&A Strategies: Pharmaceutical companies are increasingly prioritizing clinical-stage and late-stage programs, particularly those supported by clear human data, indicating a market preference for mature assets that demonstrate safety and efficacy.
- OT-101 IP Expansion: Oncotelic Therapeutics recently announced the expansion of international intellectual property coverage for OT-101, enhancing protection across neurology, oncology, and CNS drug delivery technologies, thereby solidifying its market position in these areas.
- Importance of Clinical Validation: Biopharmaceutical deal activity reflects a growing preference for programs that have achieved clinical validation, particularly in oncology and CNS, highlighting investors' focus on reducing development risks associated with drug discovery.
- Cross-Applicability Platforms: Oncotelic's TGF-β modulation strategy illustrates its broad application potential across oncology and neurological diseases, indicating the company's pursuit of greater market opportunities across multiple indications, thereby enhancing its long-term strategic value.
See More
REGENXBIO Faces FDA Challenges for Gene Therapy Approval
- FDA Response Letter Issued: REGENXBIO's shares fell after receiving a response letter from the FDA regarding its Hunter syndrome gene therapy, indicating regulatory concerns about trial design that could delay the approval timeline.
- Trial Design Concerns: The FDA's questioning of the trial design may impact the efficacy assessment of the therapy, negatively affecting REGENXBIO's market outlook and increasing uncertainty for investors.
- Approval Timeline Delayed: Due to the FDA's feedback, REGENXBIO may need to reevaluate its clinical trial plans, which will push back the originally scheduled approval timeline and affect the company's future revenue expectations.
- Negative Market Reaction: The stock price decline following the FDA's response letter reflects market concerns about REGENXBIO's future direction, potentially leading to decreased investor confidence and impacting its ability to raise funds.
See More
REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
- FDA Approval Update: The FDA has accepted REGENXBIO's RGX-121 BLA under the accelerated approval pathway; however, the PDUFA goal date has been extended from November 9, 2025, to February 8, 2026, indicating the agency's cautious approach to expedited approvals.
- Reasons for CRL: The FDA issued a Complete Response Letter (CRL) for RGX-121, citing concerns regarding study eligibility criteria and the appropriateness of a surrogate endpoint, suggesting that new studies and long-term follow-ups may be necessary, which poses challenges in an ultra-rare disease population.
- Market Reaction: Despite regulatory hurdles, REGENXBIO's stock shows strong momentum in the market, with analysts maintaining a
See More
Denali Therapeutics Advances in Hunter Syndrome Treatment
- Clinical Trial Update: Denali Therapeutics reported significant biomarker reductions in its Phase 1/2 trial for Hunter syndrome (MPS II), with tividenofusp alfa (DNL310) achieving an 80% mean reduction in cerebrospinal fluid heparan sulfate, indicating its potential to address the full disease spectrum.
- Launch Readiness: The company is preparing for the April 5, 2026 PDUFA date, with plans to submit a Biologics License Application (BLA), which would provide much-needed treatment options for patients with Hunter syndrome.
- Sanfilippo Syndrome Research: Preliminary data from the Phase 1/2 study of DNL126 (ETV:SGSH) in Sanfilippo syndrome showed an 83% mean reduction in cerebrospinal fluid heparan sulfate among 20 participants, offering new hope for treatment in a field lacking effective therapies.
- Pompe Disease Clinical Design: Denali presented the Phase 1 clinical study design for DNL952 (ETV:GAA) in Pompe disease, aimed at evaluating safety and tolerability across different dosing regimens, highlighting the therapeutic potential for muscle and nervous system manifestations.
See More
Denali Therapeutics Presents Clinical Data at WORLDSymposium 2026
- Clinical Data Presentation: Denali Therapeutics will showcase clinical and preclinical data from its Enzyme Transport Vehicle (ETV) programs at the 2026 WORLDSymposium, highlighting the potential for delivering enzyme replacement therapies throughout the body, including the brain.
- FDA Priority Review: The Biologics License Application for DNL310 (for Hunter syndrome) is under FDA Priority Review, with a decision expected by April 5, 2026, which could expedite its market entry.
- Multiple Oral Presentations: Two oral presentations will discuss clinical study data for DNL310 and DNL126 (for Sanfilippo syndrome type A), demonstrating the company's progress in rare disease research.
- Poster Presentation Content: Denali will also present several posters, including a health outcomes analysis for MPS II patients and the study design for DNL952 (for Pompe disease), further solidifying its leadership in rare disease treatments.
See More
